Drug Profile
Research programme: HCV polymerase inhibitors - Afea Pharmaceuticals
Alternative Names: AT 337; AT-511Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Afea Pharmaceuticals
- Class Purine nucleotides
- Mechanism of Action Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 11 Nov 2016 Pharmacokinetics and pharmacodynamics data from preclinical studies in Hepatitis C presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)